أستراليا - الإنجليزية - APVMA (Australian Pesticides and Veterinary Medicines Authority)

jurox pty limited - trimethoprim; sulfadoxine - parenteral liquid/solution/suspension - trimethoprim pyrimidine active 40.0 mg/ml; sulfadoxine sulfanyl active 200.0 mg/ml - antibiotic & related - cat | cattle | dog | horse | pigs | sheep | beef | bitch | boar | bos indicus | bos taurus | bovine | buffalo | bull | bullock | - actinomyces spp. | bacillus anthracis | bacterial infection | bordetella spp. | bronchitis | brucella spp. | campylobacter spp. | clostridium spp. | corynebacterium spp. | cystitis | escherichia coli (e. coli) | fusobacterium spp. | haemophilus spp. | infections of the alimentary tract | infections of the urinary tracts | klebsiella spp. | metritis | nephritis | pasteurella spp. | pneumonia | salmonella | salmonella spp. | shigella spp. | staphylococci | streptococci | urethritis | vaginitis | wound infections | abscesses | amoxycillin sensitive bacteria | anaerobic bacteria | anthrax | associated with viral disease | bacterial canker | bacterial pneumonia | bordetella bronchiseptica | brucella abortus | brucella melitensis | brucella suis | clostridium botulinum | clostridium chauvoei | clostridium fallax | clostridium feseri | clostridium hemolyticum | clostridium novyi | clostridium perfringens types | clostridium septicum | clostridium sordelli | clostridium sporogenes | clostridium tetani | escherichia

سويسرا - الإيطالية - Swissmedic (Swiss Agency for Therapeutic Products)

curatis ag - calcitriolum - weichgelatinekapseln - calcitriolum 0.25 µg, antiox.: e 320, e 321, excipiens per la capsula. - renale osteodystrophie, ipoparatiroidismo, rachitismo, osteoporosi post-menopausa - synthetika

سويسرا - الإيطالية - Swissmedic (Swiss Agency for Therapeutic Products)

curatis ag - calcitriolum - weichgelatinekapseln - calcitriolum 0.5 µg, antiox.: e 320, e 321, excipiens per la capsula. - renale osteodystrophie, ipoparatiroidismo, rachitismo, osteoporosi post-menopausa - synthetika

أيرلندا - الإنجليزية - HPRA (Health Products Regulatory Authority)

leo laboratories limited - calcitriol - capsule - 0.25 millilitre

أيرلندا - الإنجليزية - HPRA (Health Products Regulatory Authority)

leo laboratories limited - calcitriol - capsule - 0.5 millilitre

أيرلندا - الإنجليزية - HPRA (Health Products Regulatory Authority)

leo laboratories limited - calcitriol - capsule - 0.5 millilitre

أيرلندا - الإنجليزية - HPRA (Health Products Regulatory Authority)

leo laboratories limited - calcitriol - capsule - 0.25 millilitre

نيوزيلاندا - الإنجليزية - Ministry for Primary Industries

agritrade (part of pgg wrightson ltd) - glufosinate-ammonium - glufosinate-ammonium 200 g/litre - herbicide

الولايات المتحدة - الإنجليزية - NLM (National Library of Medicine)

patriot pharmaceuticals, llc - tramadol hydrochloride (unii: 9n7r477wck) (tramadol - unii:39j1lgj30j) - tramadol hydrochloride 100 mg - tramadol hcl extended-release tablets is indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. limitations of use - because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses, and because of the greater risks of overdose and death with extended-release opioid formulations [see warnings and precautions (5.1)] , reserve tramadol hcl extended-release tablets for use in patients for whom alternative treatment options (e.g., non-opioid analgesics or immediate-release opioids) are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain. - tramadol hcl extended-release tablets is not indicated as an as-needed (prn) analgesic. tramadol hcl extended-release tablets is contraindicated for: - all children younger than 12 years of age [see warnings and precautions (5.3)] - post-operative management in children younger than 1

الولايات المتحدة - الإنجليزية - NLM (National Library of Medicine)

patriot pharmaceuticals, llc. - methylphenidate hydrochloride (unii: 4b3sc438hi) (methylphenidate - unii:207zz9qz49) - methylphenidate hcl extended-release tablets are indicated for the treatment of attention deficit hyperactivity disorder (adhd) in children 6 years of age and older, adolescents, and adults up to the age of 65 [see clinical studies (14)] . hypersensitivity reactions, such as angioedema and anaphylactic reactions, have been observed in patients treated with methylphenidate hcl extended-release tablets. therefore, methylphenidate hcl extended-release tablets are contraindicated in patients known to be hypersensitive to methylphenidate or other components of the product [see adverse reactions (6.5)] . methylphenidate hcl extended-release tablets are contraindicated during treatment with monoamine oxidase (mao) inhibitors, and also within a minimum of 14 days following discontinuation of a mao inhibitor (hypertensive crises may result) [see drug interactions (7.1)] . pregnancy category c methylphenidate has been shown to have teratogenic effects in rabbits whe